Airing It Out

A Case-Based Conversation on
Managing Asthma and Chronic Rhinosinusitis With Nasal Polyps

Meeting Schedule

FRIDAY, JULY 17, 2020

1:30 PM–3:00 PM ET
REGISTER NOW

WEDNESDAY, AUGUST 5, 2020

1:30 PM–3:00 PM ET
REGISTER NOW

Program Description

Target Audience

The educational design of this activity addresses the needs of allergists, clinical immunologists, and other specialist clinicians involved in the management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) or asthma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Compare clinically relevant inflammatory processes involved in the pathophysiology of CRSwNP and asthma
  • Longitudinally evaluate patients with asthma or CRSwNP for severity of disease, control of symptoms, and treatment responses
  • Discuss the biologic treatment armamentarium for CRSwNP and moderate-to-severe asthma
  • Construct individualized treatment regimens for patients with CRSwNP or moderate-to-severe asthma based on symptoms, comorbidities, and shared clinical decision-making

Statement of Need

Disorders involving inflammation or tissue remodeling in the respiratory tract are responsible for significant patient morbidity, potential mortality, and tremendous burdens on health care systems.¹,² In the upper airways, chronic rhinosinusitis (CRS) is characterized by inflammation in the nasal cavity mucosa and paranasal sinuses.³ A quarter to one third of patients with CRS have associated nasal polyps (CRSwNP), which can obstruct the sinuses and nasal passages and are often associated with more severe sinonasal symptoms.⁴ In the lower airways, asthma is a chronic respiratory disease that affects more than 25 million Americans.⁵ Notably, asthma affects a large proportion of patients with CRSwNP, and the presence of nasal polyps has been associated with asthma disease severity.⁶ An outsized segment of asthma-related morbidity and mortality is borne by the 5% to 15% of patients who have more severe forms of the disease.⁷ Research has uncovered pathophysiologic and phenotypic associations between diseases of the upper and lower airways, such as CRS and asthma, leading to the development of novel therapies for these disorders.⁸ A number of biologic medications are now available to treat certain cohorts of patients with moderate-to-severe asthma, and recently the first biologic therapy for treatment of CRSwNP has been approved by the US Food and Drug Administration (FDA).⁹,¹⁰ Clinical immunologists, allergists, and other specialists who manage patients with CRSwNP and asthma will be increasingly tasked with personalizing the choice of treatment based on the severity of symptoms, presence of comorbidities, and disease phenotypes and endotypes. Thus, clinicians must be vigilant about staying current on the latest clinical data, treatment recommendations, and new approvals from the FDA. During this Case-in-Point™ educational program, a panel of expert faculty will guide learners through unique clinical case scenarios, sharing relevant guideline recommendations, published data, and clinical insights before a brief question-and-answer session concludes each case discussion. Program attendees will find this interactive session informative and engaging, as it combines evidence-based management strategies and real-world experience into actionable best-practice recommendations that can shape therapeutic decision-making.

References

  1. Lang DM. Allergy Asthma Proc. 2015;36(6):418-424.
  2. Bhattacharyya N, et al. Laryngoscope. 2019;129(9):1969-1975.
  3. Orlandi RR, et al. Int Forum Allergy Rhinol. 2016;6(suppl 1):S22-S209.
  4. Stevens WW, et al. J Allergy Clin Immunol Pract. 2016;4(4):565-572.
  5. Centers for Disease Control and Prevention (CDC). Asthma Facts: CDC’s National Asthma Control Program Grantees. Atlanta, GA: US Department of Health and Human Services. 2013.
  6. Fokkens WJ, et al. Allergy. 2019;74(12):2312-2319.
  7. Chung KF, et al. Eur Respir J. 2014;43(2):343-373.  
  8. Rosati MG, Peters AT. Am J Rhinol Allergy. 2016;30(1):44-47.
  9. Assaf SM, Hanania NA. Curr Opin Allergy Clin Immunol. 2019;19(4):379-386.
  10. Laidlaw TM, Buchheit KM. Ann Allergy Asthma Immunol. 2019. [Epub ahead of print].

Faculty

Joseph K. Han, MD, FARS, FAAOA

Professor, Department of Otolaryngology & Head and Neck Surgery
Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery
Chief, Division of Allergy
Eastern Virginia Medical School
ARS, President Elect
AAAAI, RROAC, Chair Elect
Norfolk, Virginia

John J. Oppenheimer, MD

Clinical Professor of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey
Clinician, Atlantic Health System
Morristown Medical Center
Morristown, New Jersey

Reynold A. Panettieri, Jr, MD

Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Accreditation Information

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

PIM designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

PIM Contact Information

For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com